FDA Approves TNKase for Acute Ischemic Stroke
The FDA has approved TNKase (tenecteplase) for treating acute ischemic stroke in adults, providing a fast, single-bolus alternative for dissolving blood clots.
Published on April 12, 2025
The U.S. Food and Drug Administration has approved TNKase (tenecteplase) for the treatment of acute ischemic stroke in adults. Notably, this thrombolytic agent is administered as a single five-second intravenous bolus, offering a faster and simpler alternative to traditional treatments such as Activase (alteplase).
Additional details from recent reports indicate that the approval, noted in sources dated March 3–6, 2025, positions TNKase as a promising option for quickly dissolving blood clots and improving stroke patient outcomes. This new therapeutic approach could streamline emergency stroke care by reducing the complexity and duration of treatment administration.